ULTOMIRIS is designed for extended inhibition and elimination of ONLY C5 through lysosomal degradation1,2

Fab regions

2 amino acid modifications to promote the release of C5 in the endosome1-3

This increases the ULTOMIRIS half-life to approximately 4 times that of eculizumab, enabling maintenance dosing once every 8 weeks

Fc region

2 amino acid modifications to enhance FcRn binding1-3

ULTOMIRIS was engineered through modification of eculizumab1

Advantages of ULTOMIRIS modifications1,2

ULTOMIRIS is less likely to be degraded with C5

ULTOMIRIS is more likely to be recycled back into circulation multiple times, increasing and extending its half-life

The precise mechanism by which ULTOMIRIS exerts its therapeutic effect in NMOSD is unknown, but it is presumed to involve the inhibition of AQP4 antibody-induced terminal complement C5b-9 deposition4

Increasing the ULTOMIRIS half-life to ~4x that of eculizumab enables maintenance dosing once every 8 weeks2,4*

*The mean (SD) terminal elimination half-life and clearance of ULTOMIRIS in adult patients with NMOSD are 64.3 (11.0) days and 0.05 (0.016) liters/day, respectively. The half-life of eculizumab is 11.25 to 17.25 days.4,5

AQP4, aquaporin-4; Fab, fragment antigen-binding; Fc, fragment crystallizable; FcRn, neonatal Fc receptor; NMOSD, neuromyelitis optica spectrum disorder; SD, standard deviation.